SimBioSys

Company profile

About SimBioSys

SimBioSys is a TechBio company that combines artificial intelligence, spatial biophysics, and data science to individualize cancer therapy and improve patient outcomes. Founded in 2017 by Dr. Joe Peterson, Dr. John Cole, and Tushar Pandey at the University of Illinois, the company emerged from a National Cancer Institute-funded research project focused on novel cancer modeling approaches. SimBioSys has developed a comprehensive platform that addresses tumor heterogeneity by analyzing tumors in their entirety, moving beyond traditional biopsies or 2D pathology slides. Their flagship product, TumorSight Viz, is FDA-cleared for breast cancer surgical planning and transforms DCE-MRI studies into visually detailed, interactive 3D representations that enable precise measurements of tumor volume and distances to anatomical features. The company's technology leverages Convolutional Neural Networks to automatically segment tumors and surrounding tissues, creating digital twins that capture the physical, chemical, and biological characteristics of tumors at tissue and cellular levels. SimBioSys serves breast surgeons, oncologists, and cancer centers with both clinical and research solutions spanning the entire continuum of patient care, from visualization and surgical planning to recurrence risk prediction and treatment response modeling. The company has grown to over 20 employees and maintains research collaborations with leading institutions including Mayo Clinic, UCLA, and the University of Chicago, with backing from premier healthtech venture capital firms and Mayo Clinic as an investor.

Company description · SimBioSys official website